Home » Clinical Trials » Leukemia » NCT04532281
NCT04532281

Clinical Trial for the Safety and Efficacy of Murine CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma

Study Summary

A Study of Murine CD19 CAR-T Cells Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies.

Want to learn more about this trial?

Request More Info

Interventions

Murine CD19 CAR-T cellsDRUG
Each subject receive murine CD19 CAR T-cells by intravenous infusion

Study Locations

FacilityCityStateCountry
The First Affiliated Hospital，College of Medicine, Zhejiang UniversityHangzhouZhejiangChina

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026